Kesselheim AS - Search Results

1

Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs.

Rome BN, Feldman WB, Desai RJ, Kesselheim AS. Rome BN, et al. Among authors: kesselheim as. JAMA Netw Open. 2021 May 3;4(5):e218816. doi: 10.1001/jamanetworkopen.2021.8816. JAMA Netw Open. 2021. PMID: 33944925 Free PMC article.

2

Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.

Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, Shrank WH. Kesselheim AS, et al. JAMA. 2008 Dec 3;300(21):2514-26. doi: 10.1001/jama.2008.758. JAMA. 2008. PMID: 19050195 Free PMC article. Review.

3

FDA approval of cardiac implantable electronic devices via original and supplement premarket approval pathways, 1979-2012.

Rome BN, Kramer DB, Kesselheim AS. Rome BN, et al. Among authors: kesselheim as. JAMA. 2014 Jan 22-29;311(4):385-91. doi: 10.1001/jama.2013.284986. JAMA. 2014. PMID: 24449317 Free PMC article.

4

Approval of high-risk medical devices in the US: implications for clinical cardiology.

Rome BN, Kramer DB, Kesselheim AS. Rome BN, et al. Among authors: kesselheim as. Curr Cardiol Rep. 2014;16(6):489. doi: 10.1007/s11886-014-0489-0. Curr Cardiol Rep. 2014. PMID: 24760423 Free PMC article. Review.

5

Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.

Yeh JS, Franklin JM, Avorn J, Landon J, Kesselheim AS. Yeh JS, et al. Among authors: kesselheim as. JAMA Intern Med. 2016 Jun 1;176(6):763-8. doi: 10.1001/jamainternmed.2016.1709. JAMA Intern Med. 2016. PMID: 27159336

6

The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.

Kesselheim AS, Avorn J, Sarpatwari A. Kesselheim AS, et al. JAMA. 2016 Aug 23-30;316(8):858-71. doi: 10.1001/jama.2016.11237. JAMA. 2016. PMID: 27552619 Review.

7

Factors Influencing Prescription Drug Costs in the United States-Reply.

Sarpatwari A, Avorn J, Kesselheim AS. Sarpatwari A, et al. Among authors: kesselheim as. JAMA. 2016 Dec 13;316(22):2431-2432. doi: 10.1001/jama.2016.17299. JAMA. 2016. PMID: 27959994 No abstract available.

8

Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers.

Kesselheim AS, Rome BN, Sarpatwari A, Avorn J. Kesselheim AS, et al. Health Aff (Millwood). 2017 Feb 1;36(2):362-370. doi: 10.1377/hlthaff.2016.1340. Epub 2017 Jan 18. Health Aff (Millwood). 2017. PMID: 28100464

9

Value-Based Pricing and State Reform of Prescription Drug Costs.

Hwang TJ, Kesselheim AS, Sarpatwari A. Hwang TJ, et al. Among authors: kesselheim as. JAMA. 2017 Aug 15;318(7):609-610. doi: 10.1001/jama.2017.8255. JAMA. 2017. PMID: 28692713 No abstract available.

10

Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration.

Naci H, Smalley KR, Kesselheim AS. Naci H, et al. Among authors: kesselheim as. JAMA. 2017 Aug 15;318(7):626-636. doi: 10.1001/jama.2017.9415. JAMA. 2017. PMID: 28810023 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results